CRBP: 1Q26: Data-Rich 2H on Deck; '701 ASCO Update Should Better Define '701's Profile

Research evidence excerpt

CRBP: 1Q26: Data-Rich 2H on Deck; '701 ASCO Update Should Better Define '701's Profile

Corbus Pharmaceuticals Holdings Inc

Key fundamental questions

Our view

What are the specific aspects of CRB-701 is designed to improve upon characteristics of the currently-marketed

CRB-701’s structure that could Padcev, an approved Nectin-4 targeting ADC, through modifications primarily

differentiate it from other ADCs in focused on the linker between the antibody and the MMAE cytotoxic payload.

the class? Padcev’s linker has limited stability, which can result in a higher level of free

circulating payload, which can cause off-target toxicities like peripheral neuropathy

and skin rash commonly seen with Padcev. In contrast, CRB-701, also a Nectin-4

targeting ADC, employs a more stable and homogeneous linker, which is designed

to keep the cytotoxic payload bound to the antibody until it reaches the tumor site,

minimizing the premature release of MMAE and reducing the incidence of toxicities.

Early clinical data suggest that CRB-701 may have similar efficacy to Padcev, with

better safety profile; sample sizes are small and the study done in China – though

we believe those early signals may read through to later studies.

In which specific disease indications As a Nectin-4 directed ADC, CRB-701 could find use in metastatic urothelial cancers,

do you see the most significant the primary indication for which Padcev has been approved. Given CRB-701's

unmet needs where CRB-701 could potentially improved safety profile, it could benefit patients who may not tolerate

provide a substantial clinical benefit? existing treatments or those who have progressed on current therapies, and if

it shows effectiveness in a post-Padcev population, could become the preferred

option in 2L+ settings.